SAS Output

24-MAR-2017 18:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 138 45 26 13 4 2 09/19/2014 238 98
            138 45 26 13 4 2      
 
    2 Y 2 Continuous Dosing 280 54 14 7 3 1 0 09/19/2014    
        3 Intermittent Dosing   59 19 14 8 4 1      
            113 33 21 11 5 1      
 
  S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 Y 1 Tissue for PD-L1 testing 1378 958 883 522 263 97 17 11/10/2015 403 161
            958 883 522 263 97 17      
 
    2 Y 2 FDA approved regimen 1378 437 410 247 142 52 7 11/10/2015    
        3 MK-3475 (Pembrolizumab)   425 394 240 128 42 8      
            862 804 487 270 94 15      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 1 1 1 1 0 0 02/06/2017 37 18
            1 1 1 1 0 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   15 11 7 3 2 1 11/03/2015 319 129
            15 11 7 3 2 1      
 
    2 E Total Registrations   3 3 2 0 0 0 11/03/2015    
            3 3 2 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   18 18 9 3 0 0 03/25/2016 259 98
            18 18 9 3 0 0      
 
No E3612-MELAN,Adv Ipilimumab±Bevacizumab 1 E Total Registrations   5 1 1 0 0 0 02/16/2015 148 57
            5 1 1 0 0 0